Corum Group Limited

FY22 Results

5 September 2022

Important Notice & Disclaimer

This presentation has been prepared by Corum Group Limited (COO or the Company or Corum). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in COO, or as an inducement to purchase any shares in COO. No agreement to subscribe for securities in COO will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licensed to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements do not guarantee of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forwardlooking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates an each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.



FY22 Financial Highlights

Metric	FY22 Result	Vs pcp	H2 vs H1
Health Services revenue	\$12.0m	+ 1%	(4)%
Underlying EBITDA	\$3.7m ⁽¹⁾	(15)% ⁽²⁾	+ 16%
Underlying NPAT	\$1.1m ⁽¹⁾	(47)% ⁽³⁾	+ 86%
Operating cashflow excl net R&D tax incentive	\$1.7m	+ 18%	+ 24%
Cash on hand	\$5.8m	(11)%	(10)%

(1) Excluding PharmX legal costs / restructuring / corporate advisory consulting \$(1.1)m

(2) Excluding PharmX + BAMM legal costs / restructuring / redundancy \$(1.3)m

(3) Excluding PharmX + BAMM legal costs / restructuring / redundancy \$(1.3)m, BAMM Settlement \$(1.5)m, fair value adjustments +\$1.7m

FY22 Operational Highlights

स् PharmX expansion and growth

- PharmXchange platform launched a digital sales and marketing solution for suppliers that improves efficiency in pharmacies
- FY22 supplier-to-pharmacy connections growth of 15%

Professional Pharmacy software progress

- Group wins in the period include Go Vita, a chain of 120 health and vitamins stores who are piloting our new Point of sale solution
- **Cyber Defence launched in H1 FY22**. This "whole of market" cyber protection product is designed to prevent increasingly prevalent ransomware attacks and ensure pharmacy patient data is protected.

Real Estate eCommerce divestment

- Our non-core e-commerce business unit was disposed of during the year.
- Consideration received of **\$0.5m cash**

Organisational development

- Upskilling of workforce, new positions to drive new initiatives and upgrading of key roles
- Restructuring to improve business efficiency



PharmX- Connecting the pharmacy industry



What is PharmX?

- Trusted & reliable pharmacy electronic order & invoicing gateway since 2006
- · Key component of the Australian pharmacy supply chain
- Connects over 99% of Pharmacies with their Wholesalers and Direct Suppliers
- · Developing presence and network in New Zealand
- Handled over \$15bn of transactions in FY22
- Corum moved to 100% ownership in September 2020



Delivering our strategy for PharmX



Increase the number of suppliers

- Make it easier for suppliers to connect
- · Deepening our engagement with suppliers
- Continue to add **new suppliers**, now with 65 suppliers using the platform. This is YoY growth of 10%, and growth since acquisition of **PharmX** of 16%.
- Long term agreements signed with key wholesalers Sigma, Symbion, Clifford Hallam as well as key supplier DHL.



Delivering our strategy for PharmX

Improving pharmacy utilisation rates

- Incentivising pharmacies to increase usage average pharmacy has 6 supplier connections.
- **Retail group agreements signed** with key retail pharmacy groups to **drive utilisation**. Agreements signed in FY22 represent approximately **900 pharmacies** including Pharmacy Platform, TerryWhiteChemmart, Blooms the Chemist and Direct Chemist Outlet will drive utilisation rates and future revenue.



LiveLife Spharmacy







PharmX Growth

Corum

Group

New Retail Group and Supplier Agreements are beginning to deliver an uplift in utilisation rates, and an increase in the number of supplier-to-pharmacy connections.





Delivering our strategy for PharmX



Developing new functionality - PharmXchange

- An Opportunity presents because the current **PharmX** business model doesn't resonate with small suppliers and therefore doesn't resolve all the manual processing issues at pharmacy level
- In addition, the current business model doesn't meet all the needs of the large suppliers such as product and promotion information, payments and supply chain inventory
- Resolving these issues allows **PharmX** to access significant revenues
- PharmXchange has been developed to address these gaps
- PharmXpay payments solution integrated into the PharmXchange platform to drive ease of transaction



PharmXchange - Enabling pharmacy trade

Pharm (purchasing) payers	ents integrated	Brands Suppliers	Payments Reso	urces			₩ 24 🕹 😭
Care starts	PEVER RELIEP? Paulor Panadol Rec. Doco	WANT FAIR ON FEVEN RELLEF Care starts Presider	and the second s	REVLON		Voltaren	ALCO
Panadol	26 Froducts Shop Brand	Panadol Children	14 Products Shop Brand	Revion	B6 Products Shop Brand	Voltaren	13 Products Shop Brand
BURT FOR FAST MAIN HELEF	Advil	Nexturn 246	C 11ABLET C 241948. C EREQUENT 3 Products	Do wellness your way	And the second s	y	S TOO SHORT SENSITIVE TEETH www. 20 Products
Advil DENTURES ARE Better with	Shop Brand	Quitting smoking is hard.	Shop Brand		shop Brand	Sensodyne Mitch	shop Brand
Polident	5 Froducts Shop Brand	Nicabate	15 Products Shop Brand	Otrivin	7 Products Shop Brand	Mitchum	16 Froducts Shop Brand
Wis	dom		K	Pienco -		Advil Centown	LEON No.3000 Otrivin Itosocras / Woltanen
Wisdom Brand	41 Products Shop Brand	Pure Living	35 Products Shop Brand	Cellife	20 Products Shop Brand	Haleon	10 Products Shop Brand



PharmXchange - Enabling pharmacy trade



- Launched in **June 22** to provide additional services to Pharmacies & Suppliers
- Highly integrated with the industry proven
 PharmX gateway
- Opportunity to develop incremental earnings stream leveraged to platform sales

Key Benefits for Pharmacies

- A feature rich tailored platform assisting
 Pharmacy efficiency
- A central, convenient platform to access a range of **Supplier Promotions**
- Fast & secure Supplier Payments using
 PharmXpay
- Opportunities to reduce manual processing through automation

Key Benefits for Suppliers

- Digital Sales and Marketing solution for Brands
 and Products
- Effective method to access and market to a large number of Pharmacies
- Allows field sales personnel to focus on high value opportunities and tasks
- Efficient way to access regional and new Pharmacy customers



PharmXchange - progress to date

PharmXchange Progress To Date

- Pilot Program announced end of June 2022
- Initial Pilot included 15 Pharmacies and 10 Suppliers
- Initial Pilot Suppliers include leading global pharmacy Suppliers Haleon (previously GSK Consumer Healthcare) and Revion
- Haleon launched full brand and product range in early August
- Pilot Program recently expanded to uplift to 100 Pharmacies
- Pharmacy interest across a broad range of Banners & Independents
- · Pipeline of over 20 Suppliers either now live or in provisioning

PharmXchange Scaling Strategy

- · Currently executing controlled rollout ahead of initial plan
- Near term focus on Controlled Rollout and Platform Operation Validation
- Extensive Supplier engagement across a broad base of Suppliers
- Progressive Pharmacy engagement with both Groups and Independents
- Opportunity to extend into other geographies and adjacent markets
 Group

Pharmacy software progress

Transitioning from legacy to new

- Strategy to increase market share by targeting groups through our relationships and market leading Head Office product
- Build on Dispense, Point of Sale and other product opportunities through these partnerships
- Transition from LOTS Dispense to Corum Clear Dispense
- Transition from LOTS POS to Corum Clear Retail
- Notable Group win in the period was Go Vita, a chain of 120 health and vitamins stores partially offset by loss of a 50 store group
- Go Vita piloting our new POS Corum Clear Retail
- Launched **Cyber Defence** a cyber protection product, in the year





Other matters - update







Recommenced after being paused temporarily pending a review of the business structure **Court Case**

Mediation in September 2022

With full hearing currently scheduled for October 2022

Now having disposed of eCommerce, we are a fully focused healthtech business looking to supplement our organic growth with value creating M&A

M&A





Financials

FY22 Financial Snapshot


Revenue growth continues, EBITDA remains positive

Results ¹	H1 FY22	H2 FY22	FY22	FY21	∆	∆ H1'22
Revenue	\$6,101	\$5,850	\$11,951	\$11,875	1%	-4%
Underlying Expenses	(\$4,404)	(\$3,877)	(\$8,281)	(\$7,539)	10%	-12%
EBITDA (reported)	\$1,385	\$1,159	\$2,544	\$2,995	-15%	-16%
EBITDA (underlying) ²	\$1,697	\$1,973	\$3,670	\$4,336	-15%	16%
EBITDA Margin (Underlying)	28%	34%	31%	37%	-6%	6%

- Health revenue growth driven by PharmX.
- Operating expenses have increased this year in line with expectations as a result of additional investment into people and skills. There has been an effort in H2 to rationalise costs where possible as can be seen in the HoH improvement of a 12% reduction in underlying costs.
- Revenue growth and trajectory continues, strong EBITDA margin of 31%

Sales Revenue (\$000's)³








¹Refer to Page 23 in the appendix for detailed financial statements. Excludes eCommerce segment now held as a discontinued operation ²Adjusted to exclude one-off costs – see Page 23 Profit & Loss for detail on underlying calculations ³FY21 and FY22 adjusted to remove eCommerce revenue. FY16-FY20 is as reported, including eCommerce

Underlying EBITDA and NPAT Bridge

Revenue growth continues, investment into people and increased amortisation drives decline in profit








¹Refer to Page 23 in the appendix for detailed financial statements. Excludes eCommerce segment now held as a discontinued operation. Adjusted to exclude one-off costs – see Page 23 Profit & Loss for detail on underlying calculations

Continued Positive Cashflow

Net cash from / (Used in) Operating Activities $(\$'000)^1$



Receipts from Customers (\$m)



- Operating cashflow of +\$1,726k excluding R&D benefit, and +\$3,281 including net R&D tax incentive received.
- Receipts from customers have grown 3% YoY driven by the contribution from PharmX. The decline HoH is mainly due to revenue decline in H2 and an increase in debtors at 30 June.
- Investment into new hires and the right skill sets to drive future revenue growth has been offset by other operational savings such as rent and travel costs resulting in improved operating cashflows of +4% YoY.
- Investment into our Clear Suite of products and PharmX assets has continued to be a core focus to drive future revenue growth.
- Closing cash on hand of \$5.8m at 30 June 2022.



FY22 Summary







Revenue growth & generating cash	PharmX Growth	Healthtech Focus
Revenue growth of 1%, below our aim of 15% growth. Healthy EBITDA margin of 31% combined with positive operating cash flows.	PharmXchange launched Strategy in place to super charge returns from this valuable industry asset.	Now having disposed of eCommerce, we are a fully focused healthtech business looking to supplement our organic growth with value creating M&A











Corporate Overview

Corum Group Limited (ASX:COO) at 26 Aug 22		Capital Structure	
Share Price	4.0cps	Shares on Issue (m)	596.8
Market Capitalisation	\$23.87m	Options / Perf Rights (m)	2.5
Enterprise Value (Cash 30/06/22)	\$18.11m	Diluted Issued Capital (m)	599.3

Share Price Performance



Profit & Loss

Profit & Loss (A\$000's)	H1'22	H2'22	FY'22	H1'21	H2'21	FY'21	Δ ΡCΡ	∆ H1'22
Revenue	\$6,101	\$5,850	\$11,951	\$5,862	\$6,013	\$11,875	1%	-4%
Health	\$6,101	\$5,850	\$11,951	\$5,862	\$6,013	\$11,875	0.6%	-4.1%
Expenses								
Materials and consumables	(\$828)	(\$571)	(\$1,399)	(\$867)	(\$732)	(\$1,599)	-12.5%	-31.0%
Employee Benefits	(\$3,098)	(\$2,940)	(\$6,038)	(\$2,881)	(\$3,188)	(\$6,069)	-0.5%	-5.1%
Marketing	(\$135)	(\$129)	(\$264)	(\$58)	(\$103)	(\$161)	64.0%	-4.4%
Technology, communication and cloud costs	(\$466)	(\$389)	(\$855)	(\$345)	(\$485)	(\$830)	3.0%	-16.5%
Legal	(\$334)	(\$558)	(\$892)	(\$384)	(\$347)	(\$731)	22.0%	67.1%
Consulting	-	(\$227)	(\$227)	(\$42)	(\$44)	(\$86)	164.0%	#DIV/0!
Other	(\$25)	(\$117)	(\$142)	(\$65)	\$46	(\$19)	647.4%	368.0%
Share based payments	(\$37)	\$16	(\$21)	-	-	-	n.a.	-143.2%
R&D tax benefit	\$207	\$224	\$431	\$197	\$418	\$615	-29.9%	8.2%
Total Expenses	(\$4,716)	(\$4,691)	(\$9,407)	(\$4,445)	(\$4,435)	(\$8,880)	5.9%	-0.5%
Statutory EBITDA	\$1,385	\$1,159	\$2,544	\$1,417	\$1,578	\$2,995	-15.1%	-16.3%
EBITDA (Underlying)	\$1,697	\$1,973	\$3,670	\$2,189	\$2,147	\$4,336	-15.4%	<i>16.3%</i>
Depreciation and amortisation	(\$996)	(\$1,179)	(\$2,175)	(\$746)	(\$1,028)	(\$1,774)	22.6%	18.4%
EBIT (Underlying)	\$701	\$794	\$1,495	\$1,443	\$1,119	\$2,562	-41.6%	13.3%
Finance costs	(\$40)	(\$31)	(\$71)	(\$18)	(\$116)	(\$134)	-47.0%	-22.5%
Income tax (expense) / benefit	(\$261)	(\$19)	(\$280)	\$91	(\$359)	(\$268)	4.5%	-92.7%
NPAT (Underlying)	\$400	\$744	\$1,144	\$1,516	\$644	\$2,160	-47.0%	86.0 %
One-off Items								
	(4212)	(4014)	(#1 176)	(+77)	(4560)	(41 241)		
BAMM & PharmX Legal Cost & Termination Payments	(\$312)	(\$814)	(\$1,126)	(\$772)	(\$569) -	(\$1,341)		
Fair value adjustment of investments	-	-	-	\$1,727		\$1,727		
BAMM Cloud-based Head Office Solution	-	-	-	(\$1,468)	-	(\$1,468)		
Contribution from discontinued operations					180			
eCommerce contribution	(\$1)	\$235	\$234	(\$15)	\$28	\$13	1700.0%	
Statutory NPAT	\$87	\$165	\$252	\$988	\$103	\$1,091	-76.9%	89.7 %



Balance Sheet

Balance Sheet (A\$000's)	30 June 22 - FY22	30 June 21 - FY21
Current assets		
Cash and cash equivalents	\$5,759	\$6,478
Trade and other receivables	\$1,085	\$848
Inventories	\$42	\$34
Income tax receivable	\$1,549	\$1,548
Other assets	\$151	\$298
Assets related to discontinued operations	\$1 5 1	\$1,210
Total	- -	
Iotai	\$8,586	\$10,416
Non-current assets		
Property, plant and equipment	\$291	\$494
Right of use assets	\$312	\$296
Intangibles	\$20,725	\$19,285
Deferred tax assets	\$707	\$804
Security deposits	\$148	\$51
Assets related to discontinued operations Total	\$22,183	\$1 \$20,931
Iotai	\$22,105	\$20,951
Total assets	\$30,769	\$31,347
Current Liabilities		
Trade and other payables	\$3,828	\$3,528
Provisions	\$900	\$932
Lease Liability	\$303	\$280
Deferred revenue	\$83	\$152
Liabilities related to discontinued operations	-	\$1,495
Total	\$5,114	\$6,387
Non-current liabilities		
Other payables	\$1,305	\$726
Provisions	\$106	\$109
Lease Liability	\$23	\$41
Deferred Tax liability	\$1,018	\$1,143
Liabilities related to discontinued operations	-	\$11
Total	\$2,452	\$2,030
Total Liabilities	47 566	40 417
Total Liabilities	\$7,566	\$8,417
Net assets	\$23,203	\$22,930
		,
Equity		
Issued capital	\$98,366	\$98,366
Reserves	\$39	\$18
Accumulated losses	(\$75,202)	(\$75,454)
Total equity	\$23,203	\$22,930

Cashflow

Cash flow (A\$000's)	H1 FY22 \$'000	H2 FY22 \$'000	FY22 \$'000	H1 FY21 \$'000	H2 FY21 \$'000	FY21 \$'000
Cash flows from operating activities						
Receipts from customers	\$6,682	\$5,900	\$12,582	\$5,742	\$6,487	\$12,229
Payments to suppliers and employees	(\$5,990)	(\$4,849)	(\$10,839)	(\$5,329)	(\$5,614)	(\$10,943)
Interest and other revenue received	\$13	\$16	\$29	\$91	\$17	\$108
Income tax paid	(\$433)	\$1	(\$432)	(\$273)	\$1	(\$272)
Research and development incentive	\$1,987	-	\$1,987	\$1,973	-	\$1,973
Cashflows from discontinued operations	\$65	(\$111)	(\$46)	\$55	\$12	\$67
Net cash from operating activities	\$2,324	\$957	\$3,281	\$2,259	\$903	\$3,162
Cash flows from investing activities						
Payments for property, plant and equipment	(\$62)	(\$34)	(\$96)	(\$178)	(\$122)	(\$300)
Payments for intangible assets	(\$2,199)	(\$1,680)	(\$3,879)	(\$2,099)	(\$1,690)	(\$3,789)
Acquisition of subsidiary	-	-	-	(\$2,097)	-	(\$2,097)
Cashflows from discontinued operations	\$25	\$311	\$336	-	-	-
Net cash used in investing activities	(\$2,236)	(\$1,403)	(\$3,639)	(\$4,374)	(\$1,812)	(\$6,186)
Cash flows from financing activities						
Proceeds from issue of ordinary shares	-	-	-	\$8,936	-	\$8,936
Share issue transaction costs	-	-	-	(\$392)	-	(\$392)
Distributions paid	-	-	-	(\$896)	-	(\$896)
Principal paid to lease liabilities	(\$169)	(\$149)	(\$318)	(\$213)	(\$189)	(\$402)
Interest paid on lease liabilities	(\$16)	(\$11)	(\$27)	(\$20)	(\$13)	(\$33)
Cashflows from discontinued operations	-	(\$16)	(\$16)	-	(\$34)	(\$34)
Net cash from financing activities	(\$185)	(\$176)	(\$361)	\$7,415	(\$236)	\$7,179
		<i></i>				
Net increase/ (decrease) in cash and cash equivalents	(\$97)	(\$622)	(\$719)	\$5,300	(\$1,145)	\$4,155
Cash and cash equivalents at beginning of the period	\$6,478	\$6,381	\$6,478	\$2,323	\$7,623	\$2,323
Cash and cash equivalents at the end of the period	\$6,381	\$5,759	\$5,759	\$7,623	\$6,478	\$6,478

Share Registry

Top holders as of 2 August 2022

Rank	Name	Units	% Units
1	LUJETA PTY LTD <margaret a="" c=""></margaret>	95,746,043	16.0
2	ARROTEX INVESTMENTS HOLDING 1 PTY LTD	60,000,000	10.1
3	NATIONAL NOMINEES LIMITED	38,742,512	6.5
4	MERSAULT PTY LTD <the a="" c="" england="" f="" family="" s=""></the>	26,766,667	4.5
5	MR DAVID GERALD MANUEL & MS ANNE ELIZABETH LEARY < MANUEL SUPER FUND A/C>	18,666,667	3.1
6	LYELL PTY LTD <genesis a="" c="" fund="" super=""></genesis>	17,388,974	2.9
7	BENKI PTY LTD	17,105,748	2.9
8	SANDHURST TRUSTEES LTD <cyan a="" c="" c3g="" fund=""></cyan>	15,761,905	2.6
9	MR JOHN LAGANA	15,621,734	2.6
10	GINGA PTY LTD <thomas a="" c="" family="" g="" klinger=""></thomas>	14,414,488	2.4
11	MRS PENELOPE KING	13,333,334	2.2
12	SEVENIRON PTY LTD <sedgwick a="" c="" super=""></sedgwick>	12,000,000	2.0
12	MR GRANT POVEY	12,000,000	2.0
14	LYELL PTY LTD <hayman a="" c=""></hayman>	10,666,666	1.8
15	CANCELER PTY LTD <clarence a="" c="" fund="" super=""></clarence>	9,900,000	1.7
16	MR DAVID GERALD MANUEL & MS ANNE ELIZABETH LEARY <manuel a="" c="" family=""></manuel>	8,000,000	1.3
17	MR TYSON WELLMAN	8,000,000	1.3
17	GABODI PTY LIMITED <gabodi a="" c="" f="" ltd="" pty="" s=""></gabodi>	7,197,334	1.2
19	LINK ENTERPRISES (INTERNATIONAL) PTY LTD	7,009,480	1.2
20	GC RETIREMENT FUND PTY LTD <gc a="" c="" fund="" retirement=""></gc>	6,666,667	1.1
Total Top 2	0 holders of FULLY PAID ORDINARY	414,988,219	69.4%
Total issue	d capital of FULLY PAID ORDINARY	596,756,789	100.00%



Corum Group Limited

Contact:

Investor.Relations@corum.com.au